Production of Recombinant β-Hexosaminidase A, a Potential Enzyme for Replacement Therapy for Tay-Sachs and Sandhoff Diseases, in the Methyloptrophic Yeast *Ogataea minuta*

Hiromi Akeboshi,1,2 Yasunori Chiba,1,2* Yoshiko Kasahara,1 Minako Takashiba,1 Yuki Takaoka,1 Mai Ohsawa,1,3 Youichi Tajima,1,3 Ikuko Kawashima,1,3 Daisuke Tsuji,1,4 Kohji Itoh,1,4 Hitoshi Sakuraba,1,3 and Yoshifumi Jigami1,2,*

Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan; CREST, JST, Kawaguchi, Japan; Department of Clinical Genetics, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; and Department of Medicinal Biotechnology, Institute for Medicinal Resources, Graduate School of Pharmaceutical Sciences, University of Tokushima, Tokushima, Japan

Received 28 February 2007/Accepted 24 May 2007

A human lysosomal enzyme, β-hexosaminidase A (HexA; EC 3.2.1.52), hydrolyzes β-glycosidically linked N-acetylgalactosamine or N-acetylgalactosaminic residues at the nonreducing ends of glycoconjugates. With the coactivation of GM2 activator protein, HexA degrades GM2 gangliosides in the lysosome (27). HexA is composed of two subunits, α and β, with 57% similarity in their amino acid sequences. Normally, mammalian cells contain three isozymes, HexA (αβ heterodimer), HexS (αα homodimer), and HexB (ββ homodimer). HexA and HexB are the major forms, and HexS is a labile minor form (13, 32). Unlike HexA, the two homodimers are incapable of hydrolyzing GM2 ganglioside; however, there are artificial substrates that are hydrolyzed by all three isozymes. Deficient HexA activity leads to a lysosomal storage disease known as GM2 gangliosidosis, which causes neuronal pathologies. There are three types of GM2 gangliosidosis: Tay-Sachs disease (TS), Sandhoff disease (SD), and AB variant, with defects in the α-subunit, β-subunit, and GM2 activator protein, respectively.

For the treatment of lysosomal storage diseases (including GM2 gangliosidosis), chemical chaperones (3, 42), substrate deprivation (2, 5), enzyme replacement (4, 9, 38, 46), gene therapy (1, 17, 20, 39), and bone marrow transplantation (14, 29) have been attempted. Of these methods, enzyme replacement therapy (ERT) is a strategy that has been clinically approved for Gaucher disease (4), Fabry disease (9, 38), Pompe disease (18, 45), and mucopolysaccaridosis I (46), II (28), and VI (12). Because ERT provides fully active recombinant enzymes that are produced in mammalian cells, it is suitable for most patients with or without expression of the enzyme responsible for the disease, and no complicated surgery is required. The administered recombinant enzymes harbor mannose or mannose-6-phosphate (M6P) residues in N-glycans; these residues are recognized by the respective receptors on the cell surface and incorporated into the cell.

At present, the recombinant enzymes prescribed for ERT have been produced in mammalian cells because the glycan structure is similar to that of native enzyme. This similarity is preferable because of the necessary M6P exposure and the antigenicity that could be caused by the heterogenic glycan structure of recombinant enzymes. However, it is expensive to produce adequate amounts of protein for therapeutic purposes

* Corresponding author. Mailing address for Y. Jigami: Research Center for Glycoscience, AIST Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan; Phone: 81-29-861-6160. Fax: 81-29-861-6161. E-mail: jigami.yoshi@aist.go.jp.

Published ahead of print on 8 June 2007.
from mammalian cells. Chiba et al. (8) produced recombinant α-galactosidase A (α-GalA) in a modified yeast strain; they manipulated Saccharomyces cerevisiae to synthesize glycoprotein that lacks the outer chain of N-glycan, a structure specific to yeast but not to humans. The purified recombinant α-GalA was effectively introduced into Fabry patient fibroblasts and a Fabry mouse model and successfully hydrolyzed accumulating substrates (8, 37). These results support the possibility of using yeast as a host to produce recombinant enzymes for ERT.

Because HexA is the only one of the three isoenzymes that hydrolyzes GM2 ganglioside, administration of HexA is indispensable for ERT of TS and SD. The replacement of recombinant β-hexosaminidases in CHO cells applied to SD mouse microglia, Schwann cells, and SD human fibroblasts has been reported (33, 44). To further investigate the use of ERT for GM2 gangliosidosidosis, in this report we have produced yeast recombinant HexA that can be incorporated into TS and SD cells and hydrolyzes accumulating intracellular GM2 gangliosides. While α-GalA was produced in S. cerevisiae (8), the expression of HexA was performed in the methylotrophic yeast Ogaata minuta. We chose O. minuta as a host for HexA expression for two reasons: the methylotrophic yeast is more suitable for massive production of recombinant enzymes than S. cerevisiae, as suggested by greater α-GalA expression in Pichia pastoris (7) than in S. cerevisiae (8), and the och1-disrupted strain of O. minuta (TK5-3) produces glycoprotein without an outer chain specific to yeast glycoprotein (19), which potentially solves the problem of antigenic glycans. Recombinant HexA was successfully expressed as a heterodimer of α- and β-subunits and examined for its ability to be utilized for ERT of TS and SD.

MATERIALS AND METHODS

Materials. The methylotrophic yeasts Ogaata minuta strain TK5-3 (och1Δ α-glucose and Δade1Δa), kindly provided by Kirin Brewery Co., Ltd. (19), and Pichia pastoris strain GS115 (his4A) (Invitrogen, Carlsbad, CA) were used to express recombinant human β-hexosaminidase and M6P receptor domain 9 (Dom9His), respectively. Cultured skin fibroblasts from a patient with SD and a healthy subject were established and maintained in our laboratory (33). TS WG1051 fibroblasts (21) were obtained from the Repository for Mutant Cell Strains (Montreal, Canada). Anti-human HexA antibody was prepared from rabbit (16, 43). The following materials were purchased from commercial sources: human placenta β-hexosaminidase, Sigma-Aldrich (St. Louis, MO); chromatography medium for purification, GE Healthcare Bio-Sciences Corp. (Piscataway, NJ); medium for fibroblasts, Gibco (Grand Island, NY); broth for bacteria and yeast strains, Becton Dickinson and Co. (Franklin Lakes, NJ); and jar fermentor and medium for fibroblasts, Gibco (Grand Island, NY); broth for bacteria and yeast strains, Becton Dickinson and Co. (Franklin Lakes, NJ); and jar fermentor and process control system, YELEA (Tokyo Rikakikai Co., Tokyo, Japan).

Construction of expression plasmids. The α- and β-subunit genes, HexA (accession number NM_000520) and HEXB (accession number M19735), were amplified by PCR from cDNA provided by R. L. Proia (NIH). Amplified HEXA and HEXB fragments were inserted into expression vectors for O. minuta with markers URA3 (19) and ADE1, respectively. The constructed plasmids pOMEA1-HexA, amplified by sense primer (5'-CGAAAATCTTAGAATGACAAAGC-3') and antisense primer (5'-AGGATCCCTCAGGTCTGTTCAAACTCTTGTGCTC-3'), and pOMEA1-HexB, amplified by sense primer (5'-ATTCTTAGAATTGTCAGGCTGGCGTTCTG-3') and antisense primer (5'-GCCTCTAGATATCCATGTCTTATGGT-3'), were designed to express the α- and β-subunits of HexA, respectively, with their own secretion signal sequences. The fragment coding for only mature β-subunit (HXB) was from Ala92 to Met600 (with numbering according to the sequences shown below in Fig. 2C) was also amplified by PCR with a sense primer (5'-TAATCTTAGACCGGCGCCAAAGC-3') and antisense primer (5'-CGCCCTCTAGATACGATCTTATGGT-3'), and the fragment was first inserted into the XbaI site of pUC19. After confirmation of the sequence, the Smal and HindII fragment was inserted into the SrfI site of pOMEA1-His6, an expression vector for O. minuta with the ADE1 marker (pOMEA1-HisHEXB). This plasmid was designed to express mature β-subunit with α-factor pre-pro and the His tag sequences attached to its N terminus as a secretion signal and an affinity tag for purification. Recombinant Dom9His was produced from P. pastoris GS115 as described by Hancock et al. (11), except that the human kidney cDNA library (Marathon-Ready cDNA; Clontech, Mountain View, CA) and pPIC9 (Invitrogen) were used as the template and expression vector, respectively.

Transformations of methylotrophic yeast. O. minuta TK5-3 was transformed with NotI-digested pOMEU1-HExA and pOMEA1-HExB for the expression of recombinant HexA without the His tag. For the expression of His-tagged HexA, pOMEA1-HisHEXB was used instead of pOMEA1-HExB. The O. minuta cells used for transformation were prepared as described by Kuroda et al. (19). The transformation of P. pastoris for expression of Dom9His was performed according to the manufacturer's instructions.

Expression and purification of recombinant β-hexosaminidase isoforms and Dom9His. The transformed O. minuta was precultured in 100 ml of YPAD broth (2% peptone, 1% yeast extract, 2% glucose, and 0.2 mg/ml adenine) and then transferred to 6 liters of BMGY broth (6% peptone, 1% yeast extract, 1.34% yeast nitrogen base without amino acids, 1% glycerol, and 0.1 M potassium phosphate [pH 6.0]) in a jar fermentor. When the glycerol was completely consumed, methanol was added as a carbon source and inducer. Methanol induction was performed at 26 to 28°C and continued until the 4-methylumbelliferyl-β-glucosaminide (MUG; Sigma-Aldrich)-hydrolyzing activity in the culture broth reached saturation. The temperature and dissolved oxygen concentration were monitored and controlled by a computer during fermentation. After the induction, the supernatant of the cultured medium was concentrated by ultrafiltration (Microza UF; Asahi Kasei Chemicals Corp., Tokyo, Japan) and collected as a crude enzyme.

The crude enzyme without His tag was partially purified with a HiTrap butyl column (GE Healthcare Bio-Sciences Corp.) followed by a HiTrap DEAE column (GE Healthcare Bio-Sciences Corp.). DEAE chromatography was performed to separate isoforms by a NaCl gradient (0 to 300 mM) as previously described by Tsuji et al. (44), with a slight modification in the program of elution of isoforms. Three fractions with MUG-hydrolyzing activity were separately collected as recombinant HexB (ββ), HexA (βδ), and Hex (αα); these fractions were eluted at NaCl concentrations of 50 mM, 90 to 150 mM, and 190 to 250 mM, respectively.

To purify His-tagged HexA, the crude enzyme that contained HexA (heterodimer of α- and His-tagged β-subunits), HexS (homodimer of α-subunits), and a trace amount of HexB (homodimer of His-tagged β-subunits) was adjusted to pH 7.2 and applied to a HisTrap column (GE Healthcare Bio-Sciences Corp.), an affinity column for His-tagged protein. His-tagged HexA was eluted with 100 mM imidazole in sodium phosphate buffer (pH 7.2) containing 500 mM NaCl, and the elution was desalted and concentrated. The use of a yeast-derived column for ERT requires enzyme to be free of M6P residues, because the M6P in yeast N-glycans is covered by mannose residues and positioned a few residues inside from the nonreducing end. The α-mannosidase purification of treated enzyme was performed as described previously (8), and the HexA was recollected by using a HisTrap column. The purified enzyme was named M6PHexA.

Dom9His was expressed and purified according to the method described by Reddy et al. (36). All chromatograms were performed at 4°C under the recommended conditions for the respective columns.

Enzyme assays. β-Hexosaminidase activity was assayed with MUG (Sigma-Aldrich), 4-methylumbelliferyl-β-N-acetyl-D-glucosaminide (MUGS; Calbiochem, San Diego, CA), and 4-nitrophenyl N-acetyl-D-glucosaminide (pNP-GlcNAc; Sigma-Aldrich) as substrates (34, 41). Enzyme activity was determined as the amount of 4-methylumbelliferone or 4-nitrophenol liberated in 1 h at 37°C per mg of protein.

To detect GM2 ganglioside degradation, the following reaction mixture was prepared in a total volume of 200 μl: 8 μg of GM2 from bovine brain (Sigma-Aldrich), 20 μg of bovine serum albumin, 200 μg of sodium taurodeoxycholate, and 300 nmol/l (toward MUGS) of HexA or human placenta β-hexosaminidase (Sigma-Aldrich) in 20 mM McIlvaine buffer (pH 4.2). This reaction mixture was incubated at 37°C for 1, 3, and 24 h. The reaction was terminated by boiling, desalted with a Sep-Pak column (Waters Corp., Milford, MA), dried in a vacuum, and redissolved in 50 μl of methanol. The methanol suspension was used in thin-layer chromatography (TLC) performed by a solvent system of chloroform–methanol--0.2% CaCl2 (60/35/8, vol/vol/vol). Then, resorcinol reagent (2 mg/ml resorcinol, 80% HCl, and 0.25 mM CuSO4) was sprayed onto the plate and heated at 115°C for 30 min.

The amount of protein was measured using the BCA protein assay reagent kit.
TABLE 1. Purification of recombinant HexA and M6PHexA

<table>
<thead>
<tr>
<th>Step no.</th>
<th>Purification method</th>
<th>Protein (mg)</th>
<th>Total activity (mmol/h)</th>
<th>Sp act (mmol/h/mg)</th>
<th>Recovery of MUG (%)</th>
<th>Purification (fold) of MUG</th>
<th>MUG/MUGS ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Culture supernatant, 4 liters</td>
<td>1,500</td>
<td>74</td>
<td>43</td>
<td>0.051</td>
<td>0.029</td>
<td>100 (23)*</td>
</tr>
<tr>
<td>2</td>
<td>HisTrap (HexA)</td>
<td>7.6</td>
<td>11</td>
<td>4.3</td>
<td>1.4</td>
<td>0.57</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>Mannosidase treatment</td>
<td>16</td>
<td>7.9</td>
<td>3.2</td>
<td>0.51</td>
<td>0.20</td>
<td>11</td>
</tr>
<tr>
<td>4</td>
<td>HisTrap (M6PHexA)</td>
<td>3.3</td>
<td>4.9</td>
<td>1.7</td>
<td>1.5</td>
<td>0.50</td>
<td>6.6</td>
</tr>
</tbody>
</table>

*Amount of HexA in the total isozymes, calculated from their ratio as detected by DEAE elution. Steps 2 and 4 describe purified HexA and M6PHexA, respectively.

N-terminal analysis of recombinant HexA. Purified HexA was treated with endoglycosidases H (EndoH; New England BioLabs, Ipswich, MA) according to the manufacturer’s instructions. It was then used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), blotted onto polyvinylidene difluoride (PVDF) membrane, and stained with Coomassie brilliant blue (CBB). The two SDS-PAGE bands were analyzed by Edman sequencing using the Procise 494 HT protein sequencing system (Applied Biosystems, Foster City, CA).

Preparation of antibodies against HEX α- and β-subunits. Polyclonal antibodies for detecting HEX α- and β-subunits were prepared in rabbits by using two keyhole limpet hemocyanin-conjugated synthetic peptides that corresponded to amino acids 277 to 289 of the α-subunit (CYSGSEPSGIWGP) and amino acids 556 to 571 of the β-subunit (CR-LRLWSDKDVRMDDDAY) as antigens (numbering according to Fig. 2B and C, below). The antibodies recognized both the mature and precursor forms of the proteins on immunoblotting.

Detection of M6P exposed on N-glycans. Interaction between the recombinant enzyme and the M6P receptor was detected by receptor staining with Dom9His produced from Pichia pastoris. A pair of blotted PVDF membranes was prepared from HexA and M6PHexA that was subjected to SDS-PAGE. One membrane was used to perform immunostaining with anti-human HexA serum, and the other membrane was used to detect molecules interacting with Dom9His in combination with the PentaHis-horseradish peroxidase conjugate kit (QIAGEN, Hilden, Germany). Briefly, after the membrane was blocked, it was incubated with Dom9His, followed by anti-His antibody conjugated with horseradish peroxidase-oxidase solution (QIAGEN). The Dom9His bound to M6PHexA was detected with the ECL plus Western blotting detection system (GE Healthcare BioSciences Corp.). The detection patterns of both membranes were compared.

N-glycan analysis. The percentage of N-glycan that contained M6P was determined by high-performance liquid chromatography (HPLC) analysis of pyridylamine (PA)-labeled N-glycans from recombinant HexA. Briefly, the N-glycans in HexA were isolated by digestion with peptide N-glycosidase F (PNGase F; Pierce, Rockford, IL). The detection patterns of both membranes were compared.

Expression, purification, and characterization of recombinant HexA. Cultured broth of recombinant O. minuta was separated with a HiTrap DEAE column to estimate the ratio of isozymes produced. Compared to that of mammalian β-hexosaminidase (44, 48), the recombinant β-hexosaminidase produced in yeast displayed a different pattern on an anion exchange chromatogram (HiTrap DEAE column) (data not shown). The ratio of HexB, HexA, and HexS obtained by DEAE column chromatography was 1/11/35, suggesting that the amount of HexA produced is about 23% of the total isozymes produced and that HexB, the most abundant isozyme in mammalian cells, was barely produced in yeast.

For rapid purification of HexA with a high recovery using an immobilized metal affinity column, His-tagged HexA (His tag attached to the N terminus of the β-subunit) was prepared. The tag attached to the recombinant enzyme may create a problem with antigenicity, which would make the tagged recombinant enzyme unsuitable for ERT. However, since the experiments in this study were performed only in vitro or in situ to examine the possibility of yeast recombinant proteins for therapeutic usage, the antigenicity of the His tag was not a concern at this stage. Therefore, for further experiments in this report, His-tagged HexA was used.

His-tagged recombinant enzyme was purified from the culture broth of HexA-expressing O. minuta in a jar fermentor and was purified as shown in Table 1. Neither HexB nor HexS was detected in the Western blotting analysis on native PAGE of purified HexA when using anti-HexA, anti-α-subunit, and anti-β-subunit antibodies (data not shown), suggesting that HexA is effectively purified by the HisTrap column. The ratio of MUG- to MUGS-hydrolyzing activities of purified HexA and M6PHexA increased to 2.6 and 2.9 from the value for crude enzyme (1.7), respectively. This value is slightly lower than the reported values (3.5 to 4.0) for CHO recombinant HexA (15, 44). The purified HexA and M6PHexA from four batches of culture were combined and used for further investigations.

The amount of recombinant β-hexosaminidase isozymes
produced from yeast cells in 1 liter of culture broth was about 57 mg, of which 23% (13 mg) was HexA, based on the ratio of isozymes separated by the DEAE column. The SDS-PAGE and immunostaining analysis of purified HexA and M6PHexA (Fig. 1) showed two major bands, probably derived from the α- and β-subunits. The SDS-PAGE pattern of deglycosylated HexA by EndoH showed two bands with apparent molecular masses of 46 kDa and 43 kDa (Fig. 2A). The N-terminal amino acid sequence of the 46-kDa band was identified by a protein sequencer as a mixture of G85KRHT, R87HTLE, and H88TLEK, and that of the 43-kDa band was identified as T166QVQQ (numbered according to the sequences in Fig. 2). The sequence of the 46-kDa band, which was determined to be the mature α-subunit, started several amino acid residues upstream of native enzyme, starting from T89 (Fig. 2B). The sequence of the 43-kDa band, which was determined to be the β-subunit, was processed at a single site starting from T166 (Fig. 2C), as reported for human HexA (24, 35). Based on the size estimated from SDS-PAGE, the second processing site of the β-subunit (R356QNK) (Fig. 2C) was not processed in the O. minuta recombinant protein. From the primary structure of the β-hexosaminidase subunits, the molecular mass of the processed α-subunit from Gly85, Arg87, or His88 to the C terminus (Thr) is 50.7 to 51.0 kDa and that of the β-subunit is 49.9 kDa (Thr166 to Met). Differences in the molecular mass of a protein often occur between the molecular mass deduced from SDS-PAGE and that calculated from the primary structure, and a similar result was observed for the α- and β-subunits of HexA. The C terminus of the β-subunit, however, appears to be truncated in O. minuta recombinant HexA, as described in the Discussion section, below.

Enzymatic activities towards artificial substrates and GM2 ganglioside. The specific activities of recombinant HexA for MUG, MUGS, and pNP-GlcNAc were 1.2 ± 0.2, 0.5 ± 0.01, and 1.5 ± 0.1 mmol/h/mg (mean ± standard error), respectively, and those of M6PHexA were 1.7 ± 0.3, 0.7 ± 0.1, and 2.6 ± 0.2 mmol/h/mg, respectively. The activity towards native substrate, GM2 ganglioside, was detected under in vitro conditions using sodium taurodeoxycholate as a detergent in place of GM2 activator protein (23). Recombinant HexA and de-salted human placenta β-hexosaminidase with an activity of 300 nmol/h (toward MUGS) were incubated with GM2 ganglioside at 37°C for 1, 3, and 24 h. The TLC pattern for hydrolysis showed that the recombinant HexA hydrolyzed GM2 ganglioside and yielded GM3 ganglioside in the same manner as the human enzyme (Fig. 3). The complete degradation of GM2 ganglioside (8 μg) was observed within 24 h when HexA with a MUGS-hydrolyzing activity of 500 nmol/h was added to the reaction mixture (data not shown).

Exposure and content of M6P on recombinant HexA. To detect M6P exposure on the N-glycan of M6PHexA and its recognition by the M6P receptor, immunostaining and recep-

FIG. 1. Analysis of HexA and M6PHexA by SDS-PAGE (A) and Western blotting (B). Purified HexA and M6PHexA were separated by 10% SDS-PAGE and analyzed by CBB staining (A) and immunostaining (B). The blotted membrane was overlaid with rabbit anti-human HexA serum, followed by alkaline phosphatase-conjugated anti-rabbit immunoglobulin G as the secondary antibody. CDP-Star detection reagent (GE Healthcare Bio-Sciences Corp.) was used to visualize the enzymes. M, molecular marker; lane 1, HexA; lane 2, M6PHexA.

FIG. 2. Primary structure and inner processing sites of the α- and β-subunits of human HexA. (A) EndoH-treated HexA blotted onto PVDF membrane and stained with CBB. The EndoH treatment was performed according to the manufacturer’s instructions. The two major bands (α and β) were analyzed for their N-terminal sequences. The primary structures of the α-subunit (B) and the β-subunit (C) of HexA are shown. Asterisks show the N-terminal amino acid detected by protein sequencing. Signal sequences are shown by the arrows. Amino acids that are proteolytically processed in mammalian HexA are boxed.
tor staining of HexA and M6PHexA were performed using anti-HexA antibody and Dom9His, respectively (Fig. 4). Of the 15 domains that compose the cation-independent M6P receptor, domain 9 demonstrates high affinity to M6P even when it is expressed alone as a truncated form (10, 11, 36). HexA was detected only by the anti-HexA antibody, while M6PHexA was detected by both the antibody and Dom9His (Fig. 4, lane 2). These results indicate that M6P residues on HexA N-glycan were properly uncovered by α-mannosidase treatment. However, some of the M6PHexA molecules, especially those of low molecular weight, were detected only by anti-HexA antibody and not by Dom9His (Fig. 4, lane 2). The M6PHexA molecules that were unrecognized by Dom9His probably do not contain acidic sugars (M6P) residues on their N-glycans; they probably lost most of the mannose residues on their N-glycans due to the α-mannosidase treatment.

To determine the M6P content of HexA, N-glycans were enzymatically separated from HexA by using PNGase F and analyzed by HPLC (Table 2). About 6% of the total N-glycan was phosphorylated, while over 90% of the N-glycans were not phosphorylated. Regardless of phosphorylation, the length of mannose residues on HexA N-glycans varied from 8 (Man9GlcNAc2) to 15 (Man15GlcNAc2), with 10 mannose residues (Man10GlcNAc2) the most abundant.

Uptake of M6PHexA by TS and SD fibroblasts and observation of intracellular GM2 ganglioside. The incorporation of recombinant HexA into TS and SD fibroblasts was determined by restoration of MUGS-hydrolyzing activity in cell homogenates. The residual activity of M6PHexA in the medium at 37°C was 70% and 40%, respectively (data not shown). Ohsawa et al. (33) considered the low stability of HexA within the medium and replaced half of the medium every day with fresh medium that contained the appropriate concentration of enzyme throughout the uptake experiments. Because the residual activity of M6PHexA in the medium at 37°C was gradually reduced within 72 h of incubation (data not shown), we followed the procedures described by Ohsawa et al. (33). M6PHexA was incorporated into the TS and SD fibroblasts via M6P receptors, and its incorporation was inhibited by simultaneous addition of 5 mM M6P, while no incorporation was observed when HexA was added (Fig. 5A). These results suggest that HexA is incorporated into fibroblasts in an M6P receptor-dependent manner.

Dose-dependent incorporation of M6PHexA activity up to 1,800 nmol/h/well was observed for both TS and SD fibroblasts (Fig. 5B). The effect of incorporated M6PHexA on accumulated GM2 gangliosides in TS fibroblasts was observed by immunofluorescence analysis (Fig. 6). GM2 that accumulates in lysosomes and endosomes forms granular aggregates, which appear as spots during immunofluorescence analysis. Degradation of granular GM2 was observed dose dependently in M6PHexA-incorporated TS fibroblasts.

**DISCUSSION**

We previously produced homodimeric α-GalA, a recombinant human lysosomal enzyme, in *S. cerevisiae*; this enzyme was suitable for enzyme replacement therapy of Fabry disease (8). In the present study, we produced recombinant human β-hexosaminidase A, a human lysosomal heterodimeric glycoprotein, in the methylotrophic yeast *O. minuta* for utilization in the treatment of TS and SD. The amount of recombinant β-hexosaminidase isoforms that were produced was 57 mg/liter of broth, and both HexA and M6PHexA were obtained with greater than 90% purity, as determined by HPLC analysis (data not shown). Several groups, including our group, have produced recombinant α-GalA in various hosts. The amounts of recombinant α-GalA produced were as follows: 0.019 mg/10-cm culture dish under the expression system of COS-7 cells.

**FIG. 4.** Interaction between Dom9His and M6PHexA. Blotted recombinant enzymes were detected by anti-HexA antibody (A) and Dom9His (B), as described in Materials and Methods. Lane 1, HexA; lane 2, M6PHexA.

**TABLE 2. Analysis of HexA N-glycan**

<table>
<thead>
<tr>
<th>Sugar</th>
<th>Neutral (nonphosphorylated)</th>
<th>Acidic (phosphorylated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Man9GlcNAc2</td>
<td>14.2</td>
<td>1.1</td>
</tr>
<tr>
<td>Man10GlcNAc2</td>
<td>15.9</td>
<td>1.4</td>
</tr>
<tr>
<td>Man11GlcNAc2</td>
<td>22.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Man12GlcNAc2</td>
<td>21.5</td>
<td>1.2</td>
</tr>
<tr>
<td>Man13GlcNAc2</td>
<td>9.8</td>
<td>0.5</td>
</tr>
<tr>
<td>Man14GlcNAc2</td>
<td>3.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Man15GlcNAc2</td>
<td>1.9</td>
<td>0.2</td>
</tr>
<tr>
<td>Total</td>
<td>93.9</td>
<td>6.1</td>
</tr>
</tbody>
</table>

Man, mannose; ND, not detected. *n* = 3. The values were calculated from the peak areas under the assay conditions for HPLC, as described in Materials and Methods.

The acidic sugars include mannose-6-phosphate.
(47), 4.8 mg/liter broth in Sf9 cells (6), 0.1 mg/liter broth in S. cerevisiae (8), and 4.5 mg/liter broth in P. pastoris (7). These results suggested that O. minuta has promising potential as a host for heterologous recombinant protein expression.

We found two major differences between recombinant HexA from O. minuta and native HexA from human lysosomes: the ratio of isoforms expressed and the processing patterns, especially for the \( \beta \)-subunit. The SDS-PAGE patterns of deglycosylated HexA suggest that the second processing site (R356QNK) of the \( \beta /H9252 \)-subunit is not processed. Also, the deduced mass of the deglycosylated \( \beta /H9252 \)-subunit band on the CBB staining (43 kDa) was smaller than the calculated mass (49.9 kDa). The C terminus of the \( \beta \)-subunit is possibly truncated in the O. minuta recombinant, probably due to protease digestion specific to the yeast cell, which is not observed in mammalian HexA. This truncation can explain the difference in the ratio of isoforms expressed. Since the amino acid residues in the C terminus of the \( \beta \)-subunit participate in subunit dimerization (22, 25, 26), their truncation reduces the area of dimer interface for recombinant HexB (\( 2 \beta \)) and HexA (\( 2 \alpha \)) compared with that from mammalian cells. As a result, the truncation is likely to produce less-stable \( 2 \beta \) and \( 2 \alpha \) dimers, which explains why HexB (\( 2 \beta \)) is the minor isoform and HexS (\( 2 \alpha \)) is the major isoform in O. minuta. Although the protease responsible for the C terminus truncation of the \( \beta \)-subunit has not been identified, protease-disrupted O. minuta strains, which we have already established, may prevent the C terminus truncation of the \( \beta \)-subunit, and the isoform ratio may become closer to that of mammalian cells.

Reduced production of HexB, however, is advantageous for our yeast recombinant expression system, since recombinant HexA can be purified in one step by using a HisTrap column that binds to the His tag attached to the \( \beta \)-subunit. It appears that purified HexA (MUG/MUGS ratio, 2.6) does not contain HexB, because the MUG/MUGS ratios for recombinant HexA and HexB are about 3.5 to 4 and 200 to 300 in CHO cells, respectively (15, 44). In the case of recombinants from O. minuta, the MUG/MUGS ratio should exceed 4.0 if HexB is mixed in with purified HexA. Also, purified HexA was analyzed and confirmed not to contain other isoforms, as determined by HPLC and Western blotting of native PAGE gels with antibodies against HexA, the \( \alpha \)-subunit, and the \( \beta \)-subunit.

Lysosomal targeting in ERT requires that HexA contain exposed M6P that can interact with cell surface receptors. As shown in Table 2, about 6% of the N-glycans were phosphorylated, and most of the recombinant HexA N-glycans did not contain mannosyl phosphate residues. Such nonphosphorylated N-glycan chains are shortened, theoretically, to \( \text{Man}_{n} \text{GlcNAc}_{2} \) (\( \text{Man}_{1} \text{GlcNAc}_{1} \text{GlcNAc}_{1} \)) by \( \text{Man}_{n} \text{GlcNAc}_{2} \) -mannosidase treatment, indicating that many M6PHexA molecules are glycosylated with only \( \text{Man}_{n} \text{GlcNAc}_{2} \), with no M6P residues. Nevertheless, the successful incorporation of M6PHexA through M6P receptors was observed in both TS and SD fibroblasts in an M6P receptor-dependent manner (Fig. 5A). We anticipate that the dose dependency of M6PHexA activity

![FIG. 5. Analysis of M6PHexA uptake by TS and SD fibroblasts. (A) TS and SD fibroblasts were cultured in medium containing recombinant HexA enzymes (600 nmol/h/well, toward MUGS), and the MUGS-hydrolyzing activity of homogenates was measured to determine enzyme incorporation. 1, no enzyme addition; 2, HexA; 3, M6PHexA; 4, M6PHexA with 5 mM M6P. Each bar represents the mean of two independent experiments. The cellular MUGS-hydrolyzing activity of fibroblasts from a normal subject was 752 nmol/h/mg. Error bars represent standard errors of the means. (B) Dose dependency of enzyme uptake was determined by the addition of M6PHexA to the TS and SD fibroblasts at the MUGS-hydrolyzing activities of 200, 600, and 1,800 nmol/h/well. The MUGS-hydrolyzing activity of cell extracts was determined to detect enzyme incorporation.](image)

![FIG. 6. Analysis of intracellular GM2 ganglioside degradation in TS fibroblasts. After the TS fibroblasts were cultured in medium that contained various amounts of recombinant enzymes, they were fixed and intracellular GM2 gangliosides were detected by antibody to GM2 ganglioside. (A) TS fibroblasts; (B) TS fibroblasts plus M6PHexA (600 nmol/h/well); (C) TS fibroblasts plus M6PHexA (1,800 nmol/h/well); (D) normal fibroblasts. Bar, 10 \( \mu \)m.](image)
continues over 1,800 nmol/h/well, since the ERT effect does not reach saturation at this concentration for either type of cell (Fig. 5B). The diminishing GM2 gangliosides in the TS fibroblasts (Fig. 6) suggest a proper interaction of recombinant M6PHexA with the intracellular GM2 activator protein for hydrolysis of accumulated GM2 gangliosides. These results indicate that recombinant HexA produced in O. minuta is suited for enzyme replacement therapy of GM2 gangliosidosis.

Although a good effect for enzyme replacement is observed with a 6% M6P-containing HexA, it is necessary to distinguish the N-glycosylation sites, within the seven potential sites, that are attached with phosphorylated N-glycans. Generally, the stability of a glycoprotein decreases as the glycan content decreases. In fact, the stability of M6PHexA at 37°C in Ham’s F-10 medium was about half the stability of HexA (data not shown). Therefore, a higher N-glycan content of M6PHexA, which means a higher M6P content, is required for the efficient incorporation of enzyme into the cell and especially for the stability of the enzyme.

Recombinant human α-GalA produced by S. cerevisiae KK4 (8) contained over 60% phosphorylated N-glycan due to the constitutive expression of the MNN4 gene (ScMNN4), which is a positive regulator of mannansylphosphate transferase in the host strain (30, 31). Increased M6P content in recombinant α-GalA was observed when it was expressed from an O. minuta strain that coexpressed ScMNN4. The M6P content of recombinant HexA is expected to increase when ScMNN4 or the O. minuta homologous gene is coexpressed in the host strain. The enhanced M6P content prevents the generation of shorter N-glycans (ManαGlcNAcβ) from α-mannosidase treatment and is expected to increase the stability of M6PHexA. Stable M6PHexA will lead to more efficient enzyme replacement and GM2 degradation; the increased efficiency may possibly reduce the number of treatments and the related discomfort for TS and SD patients when it is actually employed in clinical applications. Although the effect of ERT using O. minuta M6PHexA in a mouse model of SD should be further studied and increased M6P content should be established, we believe that the production of HexA in yeast is cost conscious and useful for ERT of GM2 gangliosidosis.

ACKNOWLEDGMENTS

We thank Kousuke Kuroda and Toshihiro Komeda from Kirin Brewery Co., Ltd., for providing the O. minuta host strain and vectors, Richard L. Proia from the National Institutes of Health for providing the cDNA, and Yutaka Tatano from the University of Tokushima for helping with the purification of recombinant HexA and for useful discussions.

This work was supported by grants from CREST, JST.

REFERENCES


